Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPXK27)

Drug Name

PBI-4050 Drug Info

Synonyms

setogepram; (3-pentylphenyl)acetic acid; 2-(3-Pentylphenyl)acetic acid; 1002101-19-0; 3-Pentylbenzeneacetic acid; UNII-879OVM0Y1S; Benzeneacetic acid, 3-pentyl-; 879OVM0Y1S; 1002101-19-0 (free acid); Fezagepras; SCHEMBL289216; CHEMBL4297635; GTPL10043; PBI4050; ZINC113492390; DB15447; HY-100775A; AS-59875; CS-0062694; A1-19258; Q27895887

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]

Cross-matching ID

PubChem CID: 24749700
CAS Number: CAS 1002101-19-0
TTD Drug ID: DMPXK27

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free fatty acid receptor 1 (GPR40)	TTB8FUC	FFAR1_HUMAN	Agonist	[2]
Inflammation-related GPCR EX33 (GPR84)	TTG0MQD	GPR84_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Idiopathic pulmonary fibrosis

ICD Disease Classification

CB03.4

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Free fatty acid receptor 1 (GPR40)	DTT	FFAR1	6.14E-01	-0.08	-1.33

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of Liminal BioSciences.
2	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.